Solid Tumor Targeting CAR-T Development Service by Metabolic Enzyme Overexpression

Metabolic enzymes serve as pivotal regulators that govern the energetic and biosynthetic capacity of CAR-T cells, directly influencing their efficacy and longevity within the immunosuppressive solid tumor microenvironment. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Metabolic Enzyme Overexpression is designed to overcome these metabolic limitations through targeted genetic enhancement of key enzymes involved in nutrient utilization, redox balance, and mitochondrial fitness. By engineering CAR-T cells with reinforced metabolic circuits, we enhance their oxidative capacity, prevent functional exhaustion, and sustain antitumor activity even in nutrient-deprived and hypoxic conditions.

Introduction

Metabolic enzymes serve as pivotal regulators that govern the energetic and biosynthetic fluxes essential for CAR-T cell activation, differentiation, and long-term persistence within the immunosuppressive tumor microenvironment. By overexpressing key metabolic genes, such as those enhancing mitochondrial biogenesis or nutrient utilization, it can deliberately reprogram CAR-T cell metabolism to reinforce oxidative capacity, prevent exhaustion, and ultimately potentiate sustained antitumor efficacy.

Fig.1 Metabolic intervention to augment T cell immunotherapy.¹

Solid Tumor Targeting CAR-T Development Service by Metabolic Enzyme Overexpression at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service by Metabolic Enzyme Overexpression delivers solutions that directly address metabolic roadblocks such as nutrient deprivation, high oxidative stress, and chemical immunosuppression, translating cutting-edge scientific insight into robust, clinically viable cellular products. We specialize in engineering CAR-T cells for enhanced glucose scavenging, T cell stemness, and resistance to suppressive metabolites.

What We Can Offer

We offer a comprehensive metabolic reprogramming platform for solid tumor-targeting CAR-T cells, employing multi-pronged strategies including glycolytic enhancement, mitochondrial reinforcement, antioxidant defense, nutrient stress adaptation, and epigenetic modulation to optimize metabolic fitness, durability and anti-tumor efficacy within hostile TME.

Our Service Process

Required Starting Materials:

• Target CAR Construct Information: Details of the scFv, hinge, transmembrane, and co-stimulatory domains of your existing or desired CAR construct.
• Source T Cells/Patient Leukopak: Specification of T cell source (e.g., PBMCs, purified T cell subsets, or leukopak material).

Key Steps:

Final Deliverables:

• Comprehensive Metabolic Characterization Report: Detailed data on glucose consumption, OXPHOS capacity, and TME resistance profiles.
• Final Vector and Manufacturing Protocol: Optimized, reproducible protocol for generating the metabolically enhanced CAR T-cell product.

Key Advantages

• Proprietary Multi-Target Genetic Platform: We utilize a validated genetic cassette that simultaneously engineers for persistence, nutrient scavenging, and TME defense, employing modulators such as GLUT1, FOXO1, ADA, and PDK1.
• Customized Metabolic Strategy Design: We design a bespoke metabolic overexpression strategy tailored to your specific CAR construct, the unique metabolic profile of your target solid tumor, and your planned clinical route.
• Dedicated Immunometabolism Expertise: You receive direct technical collaboration with our specialized scientists throughout the entire project lifecycle, ensuring seamless integration and data interpretation.

FAQs

Why Choose Us?

Creative Biolabs occupies a distinctive niche in overcoming the metabolic barriers that compromise solid tumor cell therapy. Our core competency extends beyond conventional gene delivery to encompass deep expertise in immune-metabolic regulation, enabling the rational selection of genetic targets that work synergistically to sustain therapeutic efficacy.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service in our research has significantly improved the in vivo persistence and anti-tumor durability of our lead candidate, confirming the FOXO1-mediated T cell stemness signature was maintained over 90 days." J. Fy*.

"The engineered T cells' ability to thrive in glucose-deprived conditions was critical. The GLUT1 overexpression strategy facilitated sustained OXPHOS capacity, offering a distinct metabolic advantage over standard CAR-T cells that rapidly succumbed to glucose competition." S. Kz*.

"We were impressed by the ADA/PDK1 engineering. It provided unparalleled resistance to the immunosuppressive TME, leading to sustained cytokine secretion and lytic function where pharmacological interventions previously failed." A. Ln*.

How to Contact Us?

To explore the full therapeutic prospects of your CAR-T initiative, our scientific advisors are ready to engage in a detailed discussion on your target antigen and strategic development objectives.

Connect with our Scientific Team for a detailed technical consultation.

Reference

1. Rangel Rivera, Guillermo O et al. "Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy." Frontiers in immunology vol. 12 645242. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2013.00175.